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Abstract
Background: The neuroinflammatory response following traumatic brain injury (TBI) is known to be a key secondary
injury factor that can drive ongoing neuronal injury. Despite this, treatments that have targeted aspects of the
inflammatory pathway have not shown significant efficacy in clinical trials.
Main body: We suggest that this may be because classical inflammation only represents part of the story, with
activation of neurogenic inflammation potentially one of the key initiating inflammatory events following TBI.
Indeed, evidence suggests that the transient receptor potential cation channels (TRP channels), TRPV1 and TRPA1,
are polymodal receptors that are activated by a variety of stimuli associated with TBI, including mechanical shear
stress, leading to the release of neuropeptides such as substance P (SP). SP augments many aspects of the classical
inflammatory response via activation of microglia and astrocytes, degranulation of mast cells, and promoting leukocyte
migration. Furthermore, SP may initiate the earliest changes seen in blood-brain barrier (BBB) permeability, namely the
increased transcellular transport of plasma proteins via activation of caveolae. This is in line with reports that alterations
in transcellular transport are seen first following TBI, prior to decreases in expression of tight-junction proteins such as
claudin-5 and occludin. Indeed, the receptor for SP, the tachykinin NK1 receptor, is found in caveolae and its activation
following TBI may allow influx of albumin and other plasma proteins which directly augment the inflammatory
response by activating astrocytes and microglia.
Conclusions: As such, the neurogenic inflammatory response can exacerbate classical inflammation via a positive
feedback loop, with classical inflammatory mediators such as bradykinin and prostaglandins then further stimulating
TRP receptors. Accordingly, complete inhibition of neuroinflammation following TBI may require the inhibition of both
classical and neurogenic inflammatory pathways.
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Background
The role of inflammation in perpetuating the secondary
injury response following traumatic brain injury (TBI)
has received a significant amount of attention over the
last two decades and is clearly an important factor in ex-
acerbating neuronal injury. However, while many pre-
clinical studies have shown that therapeutics targeting
the immune response are effective in improving out-
come when administered in the immediate aftermath of
the injury [1–3], reports from clinical trials have been
less promising. Agents with known anti-inflammatory
properties such as corticosterone, progesterone, and
erythropoietin (EPO) have all shown no benefit to date
[4–6]. Specifically, the CRASH trial, a prospective, ran-
domized, placebo-controlled multicenter trial of the cor-
ticosteroid, methylprednisolone, in TBI, reported an
increased mortality following TBI [4]. The ProTECT III
trial utilizing progesterone was halted due to failure to
demonstrate improved outcome by the Glasgow Out-
come Scale-Extended Score at 6 months post-injury [6],
with similar findings in another clinical trial utilizing
progesterone, the SyNAPse study [5]. In addition, prom-
ising anti-inflammatory agents identified in pre-clinical
studies often have narrow therapeutic windows. For
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example, interleukin-1 antagonists appear most effica-
cious when first administered within hours following in-
jury [1, 2], with minocycline also typically delivered
within the first hour post-injury [7–9]. This may be, in
part, due to the duality of the immune response follow-
ing TBI, with some aspects of the inflammatory response
necessary to promote repair [10]. In addition, this may
also reflect that classical inflammation may be only be
half the story, with neurogenic inflammation recently re-
ported as playing a key initiating role [11–13], augment-
ing many aspects of the classical inflammatory response
[14, 15]. This review will outline the interrelationship
between classical and neurogenic inflammation, promot-
ing a better understanding of the entire neuroinflamma-
tory cascade and potentially facilitating the development
of targeted anti-inflammatory regimes that can improve
outcome following TBI.
Traumatic brain injury
TBI results from the head impacting with an object or from
acceleration/deceleration forces that produce vigorous
movement of the brain within the skull or varying combi-
nations of these mechanical forces [16]. The resultant injury
is caused by two mechanisms, either primary or secondary,
although there is some degree of overlap [17, 18]. Primary
injury is the result of mechanical forces (rotation, acceler-
ation/deceleration, and direct force applied to the head)
acting at the moment of the injury that damage the blood
vessels, axons, nerve cells, and glia of the brain in a focal,
multifocal, or diffuse pattern of involvement. The type and
severity of the resulting injury depends upon the nature of
the initiating force, as well as the site, direction, and magni-
tude of the force [19]. Contact forces generated when the
head strikes or is struck by an object generally produce
focal injuries, such as skull fractures, extradural hemor-
rhages, and contusions. In contrast, acceleration/deceler-
ation forces that result from violent unrestrained head
movement, such as in a motor vehicle accident, are associ-
ated with diffuse axonal injury (DAI) [20]. In contrast, sec-
ondary injury is a gradual process that occurs over minutes
to days as the result of cellular, neurochemical, and meta-
bolic alterations initiated by the primary insult [21]. Injury
factors that contribute to this phenomenon include meta-
bolic changes, edema formation, calcium influx, increased
oxidative stress, excitotoxicity, inflammation, and ultim-
ately, cell death via necrosis or apoptosis [22]. In particular,
inflammation is thought to contribute to much of the sec-
ondary cell injury, directly injuring cells, and facilitating
other injury factors such as oxidative stress [23] and edema
formation [24, 25].
Classical inflammatory response following TBI
A robust inflammatory response develops acutely post-
TBI and is characterized by the activation of resident
cells, migration and recruitment of peripheral leuko-
cytes, and the release of inflammatory mediators [26].
Cellular damage associated with the mechanical impact
causes the release of a number of endogenous factors
such as RNA, DNA, heat shock proteins, and HMGB1
(high mobility group box 1) which act as damage-
associated molecular patterns (DAMPs) [27]. These bind
to toll-like receptors (TLRs) activating the nuclear-
factor-κB (NFκB) and MAPK pathways leading to the re-
lease of a variety of pro-inflammatory factors including
cytokines (IL-1β, IL-6), chemokines, and immune recep-
tors [28]. Members of the TLR family are expressed by a
number of resident cells within the central nervous sys-
tem (CNS), including astrocytes, microglia, and the cere-
brovascular endothelium [29–31]. Apart from DAMPs,
the classical inflammatory response is also initiated by
the presence of extravasated blood products, comple-
ment fragments, and reactive oxygen and nitrogen spe-
cies [27, 32, 33].
This inflammatory response is signaled by a rapid rise
in the levels of cytokines and chemokines following TBI,
with release from microglia, astrocytes, cerebrovascular
endothelial cells, peripheral immune cells, and even neu-
rons [32, 34, 35]. Following a moderate diffuse TBI in
mice, for example, levels of IL-1β, tumor necrosis factor
alpha (TNFα) and IL-6 within the cortex peak at 3–9 h
post-injury, before gradually subsiding [36]. Similarly,
within clinical studies, increased levels of IL-6, TNFα,
IL-10, C-C motif chemokine ligand 2 (CCL2), and IL-8
peak within the first 2 days following moderate-severe
TBI and then return to normal over a period of several
weeks [37–39]. This spike in cytokine release has been
correlated with astrogliosis, microglial activation, and
axonal dysfunction, providing evidence of the association
between the activated immune response and brain path-
ology [40].
Immune cells are recruited to the area of injury by the
release of chemokines from the damaged neuronal tissue
[41, 42]. This cellular response to injury appears to differ
slightly depending on whether the initiating insult is pri-
marily focal or diffuse in nature. A focal injury is charac-
terized by the early infiltration of neutrophils (peaking
within a few days), followed by the migration of micro-
glia, astrocytes, macrophages, and lymphocytes to the in-
jured site [43]. Flow cytometric analysis indicates that
there is a 10- to 20-fold increase in numbers of micro-
glia compared to peripheral macrophages, suggesting
that this is predominantly a central rather than periph-
eral response [44]. In diffuse injury, little to no neutro-
phil infiltration is seen, with the early cellular response
consisting of microglial accumulation and astrocytosis
most prominent in the white matter tracts [45]. This re-
sponse amplifies over-time with Hellewell et al. indicat-
ing that the highest numbers of microglia are present at
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14 days post-injury, the latest time-point investigated in
their study [45]. Even mild TBI is associated with the in-
duction of an inflammatory response, with diffuse mTBI
in pigs showing enhanced microglial activation associ-
ated with thalamic axonal injury at 6 h post-injury [46].
The function of this inflammatory response can be
both detrimental and potentially beneficial. Both micro-
glia and astrocytes can serve a neuroprotective role im-
mediately following injury by clearing damaged cell
debris by phagocytosis, releasing anti-inflammatory cyto-
kines and neurotrophic factors, [33, 47, 48]. Indeed, nu-
merous studies have shown that at least some
inflammation is necessary following an insult to the
CNS to assist in clearing damage and preparing for re-
modeling [10, 26]. For example, ablation of proliferating
reactive astrocytes following a moderate controlled cor-
tical impact injury significantly exacerbated cortical
neuronal loss and inflammation [49]. A potential pro-
tective role for astrocytes following injury includes re-
moval of glutamate to reduce the effects of excitotoxicity
[50], with the glial scar also thought to act as a physical
barrier to prevent spread of toxic molecules. [51] How-
ever, this glial scar can also have a later inhibitory effect
on axonal regrowth and regeneration [52, 53]. Further-
more, even pro-inflammatory cytokines have an import-
ant role to play with Scherbel et al. showing that
although knockout of TNFα was beneficial in the acute
phase following injury, it had long-term deleterious con-
sequences as demonstrated by TNFα−/− mice showing
worsening of motor outcome at 1 month following a
focal TBI, which was associated with enhanced cortical
tissue loss [54]. This may relate to purported associated
neuroprotective functions of TNFα, including the ability
to reduce oxidative stress [55] and promote neuro-
trophic factor synthesis [56, 57], indicating that the
presence of at least some TNFα is needed following
injury.
In addition, activated microglia demonstrate phenotypic
subpopulations, characterized by a specific molecular sig-
nature of gene expression: M1 microglia promote a classic
pro-inflammatory state releasing pro-inflammatory cyto-
kines and oxidative metabolites, while M2 microglia are
important for tissue remodeling and suppress the inflam-
matory response [58–60]. Reports from TBI studies sug-
gest that there is an early peak in M2-like activated
microglia in the week following injury [61, 62], but this
then shifts to a maladaptive M1-like activation at later
time points. The importance of M2 microglia after TBI is
demonstrated by a study by Kumar et al., where aged mice
with an impaired M2 response had increased lesion size
following a focal injury [63]. Indeed, M1 activation can ex-
acerbate neuronal injury by triggering downstream path-
ways that culminate in oxidative damage, activation of
apoptotic cell death, and increases in permeability of the
blood-brain barrier (BBB) through modifications in its
tight junctions (Tight junctions) and matrix metallopro-
teinase (MMP) activation [64, 65]. Furthermore, pro-
longed M1-like activation hampers repair and can allow
tissue damage to persist for years after the initial injury; in
a subset of TBI patients, there is incomplete resolution of
the acute neuroinflammatory response [66]. A vicious
cycle is initiated following the original insult, where the re-
lease of pro-inflammatory factors by resident glial cells
promotes further glial activation, leading to a progressive
chronic cycle of neuroinflammation [67], which can have
neurotoxic effects on neurons through mechanisms such
as oxidative stress, apoptosis, and excitotoxicity [68].
Neurogenic inflammation
Activation of sensory unmyelinated neurons by noxious
stimuli causes the simultaneous release of neuropeptides
such as SP, neurokinin A (NKA), neurokinin B (NKB), and
calcitonin gene-related peptide (CGRP) [69]. Their release
invokes neurogenic inflammation, a neurally elicited
response with the typical features of an inflammatory re-
sponse involving vasodilation and increased vascular per-
meability [70]. CGRP is chiefly responsible for promoting
vasodilation, while SP primarily induces plasma extravasa-
tion, although it also produces a brief period of vasodila-
tion [71]. Indeed, although NKA, NKB, and SP act
synergistically [72], increases in capillary permeability are
principally mediated by SP [73, 74].
SP is an 11-amino acid peptide that is a member of the
tachykinin family which includes NKA and NKB [75];
both NKA and SP derived from the preprotachykinin-A
(PPT-A) gene by alternative splicing [76]. SP is widely dis-
tributed throughout the CNS, peripheral nervous system
(PNS), and enteric nervous systems. In the CNS, it is
present in dorsal root ganglion (primary sensory) neurons
[77] of the spinal cord and many regions of the brain in-
cluding the hippocampus, cortex, basal ganglia, hypothal-
amus, amygdala, and caudate nucleus, being more
abundant in the gray matter compared to the white matter
[78]. The biological effects of SP are mediated by the
tachykinin NK receptors, with SP preferentially binding to
the NK1 receptor, although it has some affinity for the
NK2 and NK3 receptors. NK1 receptors are expressed on
endothelial cells, astrocytes, microglia, and various types
of circulating and inflammation-activated immune cells
[79]. Transduction of the SP signal through the NK1 re-
ceptor occurs via G protein signaling and the secondary
messenger cAMP, ultimately leading to the regulation of
ion channels, enzyme activity, and alterations in gene ex-
pression [80]. There are two versions of the NK1 receptor:
the full-length version and a truncated form which lacks
the 96 residues at the C terminus [81]. This truncated
form has a diminished binding affinity for SP [79], and its
activation produces a much diminished inflammatory
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response when compared to the full-length receptor [82].
Higher levels of expression of the shorter isoform are
found in peripheral tissues, while in the brain, the longer
isoform is expressed at much higher concentrations than
the truncated version [83]. This suggests that for path-
ology within the CNS, the full-length version of the NK1
receptor is the most critical.
Role of SP following TBI
Extensive research has shown that levels of SP rise
acutely following TBI in both pre-clinical animal models
and in human tissue. Virtually, all blood vessels of the
body are surrounded by sensory nerve fibers that con-
tain SP [84]. Cerebral arteries, in particular, appear to re-
ceive a dense supply of these nerve fibers, and our
studies in TBI have demonstrated that perivascular SP
immunoreactivity increases in pre-clinical models, irre-
spective of injury model [13, 85, 86], and also in humans
[87]. It appears that SP is released early following TBI,
with increases noted in the plasma at 30 min following
TBI in rodents [13]. Furthermore, this release of SP ap-
pears to depend on the magnitude of the insult, with a
graded increase in SP immunoreactivity seen with in-
creasing severity of injury [85, 88]. Indeed, SP appears to
be a key injury marker, as levels in the plasma over the
first 4 h following injury are significantly correlated with
early mortality in clinical populations, with non-
surviving TBI patients showing significantly higher levels
than survivors [88].
Moreover, it has been shown that attenuating SP activ-
ity following TBI is beneficial to outcome [89]. The first
demonstration of neurogenic inflammation in TBI
showed that depletion of sensory neuropeptides by pre-
treatment with capsaicin results in the attenuation of
post-traumatic BBB permeability, edema formation, and
improved functional outcome [11]. Later studies, specif-
ically targeted SP by administering an NK1 antagonist
showed beneficial effects in both male [13] and female
rats [90], with a significant attenuation of post-traumatic
BBB permeability and a resultant significant reduction in
edema formation with improvement in motor and cogni-
tive outcome.
What promotes the release of SP following TBI?
It appears likely that the initial release of SP from sensory
neurons following TBI may be mediated by mechanical
activation of members of the transient receptor potential
(TRP) family, predominantly TRPV1 and TRPA1 [91].
Like all TRP receptors, TRPV1 and TRPA1 are comprised
of six-transmembrane proteins that assemble as tetramers
to form cation-permeable pores [92, 93]. Their activation
allows the influx of cations, primarily sodium and calcium,
triggering the release of neuropeptides [94, 95]. TRPV1
appears to be co-expressed in most if not all of TRPA1
expressing dorsal root ganglion neurons [96, 97], with co-
expression of both these receptors with neuropeptides in-
cluding SP [98]. Indeed, suppression of the TRPV1 recep-
tor, with the antagonist capsazepine, has been shown to
significantly reduce SP levels in a number of inflammatory
models, including a model of sepsis [99], alcohol-induced
gastric injury [100], and formalin-induced asthma [101],
with the latter study showing a similar reduction in SP
with administration of the TRPA1 antagonist, HC-030031
[101]. Furthermore, activation of both TRPV1 and TRPA1
[102–104] has been linked to increased vascular perme-
ability, a key downstream effect of SP release. TRPV1 im-
munoreactivity is prominent in astrocytes and pericytes,
which are closely associated with the vasculature, as well
as neurons [105], with the administration of capsazepine
able to reduce BBB disruption following an ischemia-
reperfusion injury [106].
TRPV1 and TRPA1 channels are considered as poly-
modal receptors that are activated by a wide range of
stimuli. For TRPV1, this includes capsaicin (the active
ingredient in chilies) [107], heat (43–52 °C) [108], pro-
tons [107], bradykinin [109], prostaglandins [110], and
arachidonic acid metabolites amongst others [111]. For
TRPA1, agonists include exogenous noxious agents
such as components of wasabi and cinnamon [98], oxi-
dized lipids [112], protons [113], and potentially cold
(<17 °C) [113, 114]. Notably, both TRPV1 and TRPA1
are also putative mechanoreceptors. Early reports iden-
tified that the long ankyrin repeat region within the N-
terminal domain of TRPA1, which assists in anchoring
the receptor to the plasma membrane, could form a
spring-like structure to sense mechanical forces [115,
116]. Indeed, TRPA1 knockout mice were found to be
less sensitive to low-intensity mechanical stimuli com-
pared to wild-type mice, and responses to high-
intensity mechanical stimulation were notably impaired
[113]. Furthermore, inhibition of TRPA1 via either gene
knockout or treatment with the antagonist HC-03001
reduced mechanically induced action firing in dermal C
fibers [117, 118], wide dynamic range, and nociceptive-
specific neurons within the spinal cord [119] and mechan-
osensitive visceral afferents in the colon [120, 121]. Studies
have also suggested that TRPV1 detects mechanical
stimuli in a variety of tissues including the urothelium
cells of the bladder [122], colonic primary afferent
neurons [123], renal pelvis [124], and retinal ganglion
cells [125, 126]. The threshold for the stimulation of
both TRPV1 and TRPA1 appears to be lowered when
there is pre-existing inflammation. Indeed, blockade
of TRPA1 was only effective in reducing low-intensity
mechanical stimulation of spinal neurons in animals
with inflammatory arthritis [119], and application of a
TRPV1 antagonist reduced Aδ-fiber unit responses
only in inflamed skin [127].
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In regard to TBI, a report by Zacest et al. showed that
TBI mechanical stimulation of sensory nerves, presumably
via TRPV1 and TRPA1, facilitates the perivascular release
of SP, with SP co-localizing with amyloid precursor pro-
tein positive (injured) neurons that supply the blood ves-
sels [87]. Apart from the initial external mechanical insult
to the brain, another acute mechanical stimulus could be
related to a brief but highly significant spike in blood pres-
sure (BP) seen following injury. In a sheep model of TBI,
BP was reported to rise markedly immediately after im-
pact, peaking at a MAP of 176 mmHg before gradually
returning to baseline over a 10-min period [128]. Similar
findings have been shown in other models of experimental
TBI [129–131]. TRPV1 receptors have indeed been shown
to respond to increased intraluminal pressure [132, 133],
with Scotland et al. showing that the normal myogenic re-
sponse to elevation of increased transmural pressure in
mesenteric small arteries in vitro was suppressed with the
application of the TRPV1 antagonist capsazepine. As such
release of neuropeptides including SP may be one of the
earliest responses to TBI, highlighting its integral role in
facilitating the inflammatory response.
How does neurogenic inflammation potentiate
classical inflammation?
Direct interaction between SP and the classical
inflammatory response
SP induces and augments many aspects of the classical
inflammatory response (Fig 1), including leukocyte
activation, endothelial cell adhesion molecule expression,
and the production of inflammatory mediators such as
histamine, nitric oxide, cytokines (such as IL-6), and ki-
nins [14, 15]. SP is a potent mast cell activator [134].
Mast cells are found within the brain on the adluminal
side of the BBB and in the leptomeninges [135], with
their degranulation found to potentiate excitotoxicity
[136] and augment and prolong numerous vasoactive,
neuroactive, and immunoactive cellular and molecular
responses to injury [137, 138].
SP also directly activates microglia and astrocytes. In-
jury induces the expression of NK1 receptors on astro-
cytes, and their activation is thought to contribute to the
transformation to reactive astrocytes, with the resultant
production of inflammatory mediators such as cytokines,
prostaglandins, and thromboxane derivatives [139–141].
Similarly SP can promote microglial activation, initiating
signaling via the NFκB pathway, which leads to the pro-
duction of pro-inflammatory cytokines [142], with
microglia producing IL-1 in response to SP [143]. More-
over, following TBI, NK1 antagonists have been shown
to significantly reduce the production of the pro-
inflammatory cytokine IL-6, as well as to decrease
microglial proliferation [144].
Role of SP in altering BBB permeability
Apart from directly augmenting the local classical in-
flammatory response, SP-related BBB disruption may
also play a role in perpetuating the inflammatory
Fig 1 Interaction between the neurogenic and classical inflammatory response following TBI
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response. The BBB is a highly selective barrier formed
by a layer of endothelial cells joined together by tight
junctions including proteins such as claudins, occludin,
junctional adhesion molecules (JAMs), and zonula oc-
cluden (ZO) proteins, which are supported by the end-
feet of astrocytes that act to support and enhance the
tight junctions [145]. Tight junctions are present at the
apical end of the interendothelial junction and closely
rely on the integrity of the corresponding cadherin junc-
tion located in the basolateral region. Ultrastructural
studies of cerebral endothelial cells indicate the circum-
ferential arrangement of the TJs which provide the bar-
rier formation required to actively restrict the movement
of small hydrophilic molecules such as sodium and par-
ticular permeability tracers between cells [146]. Given
the restrictions on paracellular transport, cerebral
endothelial cells have tightly controlled mechanisms
that enable the bidirectional transcellular passage of es-
sential molecules and the efflux of potentially neuro-
toxic substances and waste products [147]. Smaller
molecules can be ferried across via carrier-mediated
transport or ion pumps while macromolecules employ
transcytosis, which can be either receptor-mediated
transport (RMT) or adsorptive-mediated transport
(AMT), where positively charged macromolecules are
nonspecifically transported across the cerebral endo-
thelium [148]. Although the cerebral endothelium has
relatively few pinocytotic vesicles compared to periph-
eral endothelial cells [149], they can still transport mac-
romolecules via one of three vesicles: clathrin-coated
pits, the most numerous and through which most of
the RMT occurs, the smaller and less numerous caveo-
lae, capable of both AMT and RMT, and large macropi-
nocytic vesciles with nonspecific cargo [150].
Following TBI, the BBB is disrupted and this encom-
passes not just potential disruption to tight junctions
but also increased transcytosis and altered transport
properties [151–153]. This increase in the transcellular
permeability of the BBB permits the extravasation of
proteins and solutes from the cerebral vasculature into
the extracellular space within the brain, promoting
edema formation, perpetuating the inflammatory re-
sponse, and causing further neuronal injury. Import-
antly, it appears that this transcytotic activity is the
initial alteration to the BBB following TBI, which is then
followed by later loss of tight junctions and movement
via the paracellular pathway [151, 152]. An early study
by Povlishock (1978) found an increase in BBB perme-
ability as early as 3 min following a mild central fluid
percussion injury, despite the apparent integrity of the
endothelial tight junctions [154]. Notably, endothelial
vesicles assume a modified appearance and initiate the
formation of extensive networks for intracellular
transport after injury, particularly in the setting of
inflammation within the CNS [155]. Indeed, ultrastruc-
tural studies have shown that within minutes of brain in-
jury, endothelial caveolae are significantly increased in
vessel segments showing loss of BBB integrity [152, 155],
with evidence for increased vesicular formation in the
BBB of TBI patients [156, 157]. In a rat cortical cold in-
jury model that produces a pure vasogenic edema, an in-
crease in expression of caveolin-1, the key protein found
in caveolae, occurred prior to the loss of tight junctions,
represented by a reduction in the expression of occludin
and claudin-5 [152]. Notably, caveolin-1 expression was
seen in blood vessels which exhibited increased perme-
ability to proteins, indicating that this may be the initial
mechanism by which the BBB is disrupted [152]. These
findings were replicated in a controlled cortical impact
model of TBI, where caveolin-1 was increased at 1 day
following injury, prior to a decrease in claudin-5 which
occurred at day 3 following injury [151].
SP is known to promote increased permeability of the
BBB leading to increased extravasation of vascular pro-
tein into the brain extracellular space. Indeed, injured
animals show a strong co-localization of SP immuno-
fluorescence with a marker of vascular permeability,
Evan’s blue, within the cortical vasculature at 5 h post-
TBI [13]. Administration of an NK1 antagonist also
leads to a dose-dependent decrease in permeability of
the BBB following TBI, with an accompanying reduction
in cerebral edema [13]. The exact mechanisms by which
SP promotes an increase in BBB permeability are less
clear. There are previous reports that application of SP
can decrease the expression of ZO-1 and claudin-5 in
cerebral capillary endothelial cells [158], but immediately
following TBI tight junctions are intact. Alternatively, SP
may initially act to increase transcytosis via activation of
transport via caveolae.
Caveolae have been shown to mediate the transport of
molecules such as albumin, transferrin, insulin, low-
density lipoproteins, cytokines, and chemokines through
the specific localization of corresponding receptors within
the caveolae coats [159, 160]. Indeed, caveolin-1 knockout
mice were unable to transcytose albumin as evaluated via
gold-labeled immunostaining [161, 162], supporting a key
role for caveolae in the early BBB changes seen following
TBI, and consistent with the increases seen in expression
of caveolin-1 in the immediate phase following injury
[151–153]. Caveolae constitute an entire membrane sys-
tem responsible for the formation of unique endo- and
exocytotic compartments [163]. During transcytosis, cave-
olae “pinch off” from the plasma membrane to form ves-
icular carriers that rapidly and efficiently shuttle to the
opposite membrane of the endothelial cells, fuse and re-
lease their contents via exocytosis [164]. In addition to the
structural caveolin proteins, a number of signaling
molecules, including specific receptors, are known to
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localize to the caveolae pit [160, 165]. Receptor tyrosine
kinase, G-protein-coupled receptors, transforming
growth factor-beta (TGF-β) type 1 and 2, certain ster-
oid receptors and enzymes have a confirmed presence
within endothelial caveolae and may play a role in fa-
cilitating macromolecular transcytosis [166–168]. Of
particular note, the NK1 receptor, to which SP prefer-
entially binds, has been reported to localize within the
endothelial caveolae and can be manipulated to upregu-
late or relocate upon stimulation, indicating that its
presence and function is dynamic and subject to the
environment [169, 170]. Indeed, stimulation of the NK1
receptor within caveolae by SP causes PKCα to relocate
to caveolae [170], with this process previously shown to
regulate the internalization of caveolae [171], the first
step in transcytosis. Although not directly studied for
the NK1 receptor, in vitro studies have demonstrated
increased receptor-mediated transendothelial transport
of target molecules in the setting of inflammation
[172]. This suggests that the activation of a caveolae-
housed receptor may also internalize additional pro-
teins in their cargo, such as albumin, facilitating their
entry into the brain.
Within the CNS, albumin is able to activate microglia
and astrocytes leading to the release of pro-inflammatory
cytokines and chemokines (e.g., IL-1β, TNFα, MCP-1,
CXC3L1), glutamate, and free radicals promoting neur-
onal injury and amplifying the classical inflammatory
response [173–178]. Although the majority of these
studies apply albumin to isolated glial cultures [174–177],
Chacheaux et al. were able to demonstrate that direct ap-
plication of a solution containing bovine serum albumin
to the rat cortex produced similar changes in gene expres-
sion when compared to application of an agent (deoxcy-
cholic acid) that directly opens the BBB [179]. Microarray
analysis showed a comparable gene expression profile to
either treatment, with an early and persistent upregulation
of genes associated with immune response activation, in-
cluding NF-κB pathway-related genes, cytokines, and che-
mokines (IL-6, CCL2, CCL7) [179]. Indeed, recent
evidence suggests that following activation by albumin,
microglia are neurotoxic, with media taken from micro-
glial cultures exposed to albumin promoting the upregula-
tion of caspase 3 and 7 in cerebellar granule neuronal
cultures with an accompanying increase in cell death
[174]. Furthermore, when exposure to albumin was com-
bined with TLR4 activation via lipopolysaccharide (LPS), a
synergistic increase in the release of pro-inflammatory cy-
tokines was noted from cultured microglia [174]. As the
neuronal injury associated with TBI leads to the produc-
tion of DAMPs [180] that act as TLR4 agonists, influx of
albumin through a disrupted BBB would lead to more po-
tent activation of microglia. This provides another key
intersection between the classical inflammatory response,
in TLR4 activation by DAMPs, and the neurogenic in-
flammatory response, with SP release promoting albumin
influx via caveolae promoting further activation of resi-
dent immune cells.
The effects of SP on the BBB relates not only to in-
creases in permeability but also on promoting immune
cell trafficking into the CNS. Activation of SP’s preferred
receptor, NK1, has been shown to enhance leukocyte mi-
gration by exerting a chemotactic effect on monocytes
and neutrophils [181–183], increasing the expression of
adhesion molecules on endothelial cells [184–187] and
augmenting local chemokine production [188]. Indeed,
application of SP to cerebral endothelial cultures led to a
dose-dependent increase in ICAM-1 expression [184],
with this associated with an increase in T lymphocyte ad-
herence, suggesting facilitation of immune cell movement
across the BBB [187]. Thus, the release of SP following
TBI may facilitate the influx of peripheral immune cells
like T cells, macrophages, and neutrophils into the CNS,
which then further augments the local neuroinflammatory
response via production of pro-inflammatory cytokines,
reactive oxygen species, and metalloproteinases.
Exacerbation of neurogenic inflammation by
classical inflammation
Although this discussion has focused on how neurogenic
inflammation can facilitate the classical inflammatory re-
sponse, this is a two-way interaction with classical inflam-
mation further enhancing the release of neuropeptides
(Fig 1). As discussed previously, TPRV1 and TRPA1 are
responsive to a number of stimuli including the classical
inflammatory mediators bradykinin [109] and prostaglan-
dins [110], which are produced as part of the inflamma-
tory response following TBI [189, 190]; their production
would potentiate further SP release. For example, the
kallikrein-kinin system is believed to be one of the first in-
flammatory pathways activated after tissue damage [191].
Bradykinin, a nonpeptide found in blood and tissue, is
cleaved from its pro-form kininogen by the protease kalli-
krein [192], with levels found to peak within the brain at
2 h following a focal brain injury [193]. TBI is also known
to increase the activity of cyclooxygenase (COX) enzymes,
principally Cox-2 found in microglia and endothelial cells,
increasing the synthesis of prostaglandins such as PGE2
and PGF2α. Indeed, levels of PGE2 have been shown to be
elevated within 5 min following TBI [194]. In addition to
these direct activators or TRP channels, cytokines like IL-
1, IL-6, and TNFα may sensitize sensory neurons, lower-
ing the threshold for release of neuropeptides [195, 196].
Conclusion
Following TBI activation of a classical inflammatory re-
sponse only represents part of the neuroinflammatory
response. The mechanical and shear stress associated
Corrigan et al. Journal of Neuroinflammation  (2016) 13:264 Page 7 of 12
with TBI also activates TRP receptors leading to the re-
lease of neuropeptides, including SP, instigating a neuro-
genic inflammatory response. SP both directly and
indirectly, through alterations in BBB permeability with
influx of plasma proteins, augments the classical inflam-
matory response, with both classical and neurogenic in-
flammation providing positive feedback to the other to
amplify and propagate inflammation with the release of
pro-inflammatory mediators, oxidative metabolites, and
metalloproteinases amongst others, which cause further
neuronal damage. As such, modulation of neuroinflam-
mation following TBI may require addressing both in-
flammatory pathways with the aim to prevent the
deleterious effects of the response, while facilitating
repair.
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